Treating symptomatic uterine fibroids with myomectomy: current practice and views of UK consultants

R Fusun Sirkeci, Anna Maria Belli, Isaac T Manyonda, R Fusun Sirkeci, Anna Maria Belli, Isaac T Manyonda

Abstract

Background: The demand for uterus-sparing treatments is increasing as more women postpone childbirth to their 30-40s, when fibroids are more symptomatic. With an increasing choice of treatment options and changing care-provider profiles, now is an opportune time to survey current practices and opinions. Using a 25-stem questionnaire, a web-based survey was used to capture the practices and opinions of UK consultant gynecologists on the treatment of symptomatic fibroids, including the types of procedure most frequently used, methods used to reduce blood loss, and awareness and acceptability of treatment options, and to assess the impact of gender and experience of the treating gynecologist.

Results: The response rate was 22%. Laparascopic myomectomy is used least frequently, with 80% of the respondents using GnRHa preoperatively to minimize blood loss and correct anemia, while vasopressin is most frequently used to reduce intraoperative blood loss. Female consultants operate significantly less frequently than males. Those with more than 10 years consultant experience are more likely to perform an open myomectomy compared to those with less than 10 years experience.

Conclusions: Compared to a similar survey performed 10 years ago, surgical methods remain to be the most common treatments, but use of less invasive treatments such as UAE has increased. Consultants' attitudes appear to be responding to the patient demand for less radical treatments. However, it is yet to be seen if the changing consultant demographics will keep up with this demand. The low response rate warrants cautious interpretation of the results, but they provide an interesting snapshot of current views and practices.

Keywords: Consultant practices; Fibroids; GnRHa; Myomectomy; UAE; Vasopressin.

References

    1. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188:100–7. doi: 10.1067/mob.2003.99.
    1. Laughlin SK, Schroeder JC, Baird DD. New directions in the epidemiology of uterine fibroids. Semin Reprod Med. 2010;28(3):204–17. doi: 10.1055/s-0030-1251477.
    1. Schmidt L, Sobotka T, Bentzen JG, Nyboe Andersen A, ESHRE Reproduction and Society Task Force Demographic and medical consequences of the postponement of parenthood. Hum Reprod Update. 2012;18(1):29–43. doi: 10.1093/humupd/dmr040.
    1. Office for National Statistics, Births in England and Wales 2015. Available online at: . (Accessed 23 June 2017)
    1. Marshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE, Colditz GA, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997;90(6):967–73. doi: 10.1016/S0029-7844(97)00534-6.
    1. Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):571–88. doi: 10.1016/j.bpobgyn.2008.04.002.
    1. Ravina JH, Herbreteau D, Ciraru-Vigneron N, et al. Arterial embolisation to treat uterine myomata. Lancet. 1995;346:671–672. doi: 10.1016/S0140-6736(95)92282-2.
    1. The National Institute for Health and Care Excellence: Uterine artery embolisation for fibroids, NICE interventional procedure guidance [IPG367]. Available online at: . (Accessed 25 Nov 2015)
    1. Stewart EA, Gedroyc WM, Tempany CM, Quade BJ, Inbar Y, Ehrenstein T, et al. Focused ultrasound treatment of uterine fibroid tumors: safety and feasibility of a noninvasive thermoablative technique. Am J Obstet Gynecol. 2003;189(1):48–54. doi: 10.1067/mob.2003.345.
    1. Schlesinger D, Benedict S, Diederich C, Gedroyc W, Klibanov A, Larner J. MR-guided focused ultrasound surgery, present and future. Med Phys. 2013;40(8):080901. doi: 10.1118/1.4811136.
    1. Gizzo S, Saccardi C, Patrelli TS, Ancona E, Noventa M, Fagherazzi S, et al. Magnetic Resonance-Guided Focused Ultrasound Myomectomy: Safety, Efficacy, Subsequent Fertility and Quality-of-Life Improvements, A Systematic Review. Reprod Sci. 2014;21(4):465–76.2013. doi: 10.1177/1933719113497289.
    1. Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366:409–420. doi: 10.1056/NEJMoa1103182.
    1. Donnez J, Donnez O, Matule D, Ahrendt HJ, Hudecek R, Zatik J, et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril. 2016;105(1):165–173. doi: 10.1016/j.fertnstert.2015.09.032.
    1. Levens ED, Potlog-Nahari C, Armstrong AY, et al. CDB-2914 for uterine leio- myomata treatment: a randomized controlled trial. Obstet Gynecol. 2008;111:1129–36. doi: 10.1097/AOG.0b013e3181705d0e.
    1. Taylor A, Sharma M, Tsirkas P, Di Spiezio SA, Mastrogamvrakis G, et al. Surgical and radiological management of uterine fibroids – a UK survey of current consultant practice. Acta Obstet Gynecol Scand. 2005;84:478–482. doi: 10.1111/j.0001-6349.2005.00692.x.
    1. Centre for Workforce Intelligence (CfWI); Securing the future workforce supply: Obstetrics and Gynaecology stock take. Available online at: . (Accessed 23 June 2017)
    1. The Royal College of Obstetricians and Gynaecologists and The Royal College of Radiologists . Clinical recommendations on the use of UAE in the management of fibroids. Third. London: RCOG and RCR; 2013.
    1. Delnevo CD, Abatemarco DJ, Steinberg MB. Physician response rates to a mail survey by specialty and timing of incentive. Am J Prev Med. 2004;26(3):234–6. doi: 10.1016/j.amepre.2003.12.013.
    1. Cook C, Health F, Thompson RL. Meta-Analysis of Response Rates in Web- or Internet-Based Survey. Educ Psychol Measurement. 2000;60(6):821–36. doi: 10.1177/00131640021970934.
    1. Gupta S, Onwude J, Stasi R, Manyonda I. Refusal of blood transfusion by Jehovah's Witness women: a survey of current management in obstetric and gynaecological practice in the U.K. Blood Transfus. 2012;10(4):462–70.
    1. Health and Social Care Information Centre, Hospital Episode Statistics (HES), Hospital Episode Statistics Excel spreadsheets years 2013–2014. Admitted patient care 2013-2014. Available online at: . (Accessed 23 June 2017)
    1. Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev. 2001;2:CD000547.
    1. Farquhar C, Brown PM, Furness S. Cost effectiveness of pre-operative gonadotrophin releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy. BJOG. 2002;109(11):1273–80. doi: 10.1046/j.1471-0528.2002.01224.x.
    1. Talaulikar V, Belli AM, Manyonda I. GnRH agonists: do they have a place in the modern management of fibroid disease? J Obstet Gynaecol India. 2012;62(5):506–10. doi: 10.1007/s13224-012-0206-0.
    1. Luketic L, Shirreff L, Kives S, Liu G, El Sugy R, Leyland N, Solnik MJ, Murji AJ (2017) Does Ulipristal Acetate Affect Surgical Experience at Laparoscopic Myomectomy? Minim Invasive Gynecol (17):30227–3
    1. Sancho JM, Delgado VS, Valero MJ, Soteras MG, Amate VP, Carrascosa AA. Hysteroscopic myomectomy outcomes after 3-month treatment with either Ulipristal Acetate or GnRH analogues: a retrospective comparative study. Eur J Obstet Gynecol Reprod Biol. 2016;198:127–30. doi: 10.1016/j.ejogrb.2016.01.014.
    1. Al-Shabibi N, Chapman L, Madari S, Papadimitriou A, Papalampros P, Magos A. Prospective randomised trial comparing gonadotrophin-releasing hormone analogues with triple tourniquets at open myomectomy. BJOG. 2009;116(5):681–7. doi: 10.1111/j.1471-0528.2008.02022.x.
    1. Chudnoff S, Glazer S, Levie M. Review of vasopressin use in gynecologic surgery. J Minim Invasive Gynecol. 2012;19(4):422–33. doi: 10.1016/j.jmig.2012.03.022.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe